According to the recent update on COVID treatment, an experimental drug developed by an Australian researcher could help prevent deaths from COVID-19 by controlling the formation of blood clots responsible for breathing difficulties, organ failure, stroke and heart attack. Professor Shaun Jackson from the University of Sydney and the Heart Research Institute is leading a team of researchers developing a new anti-clotting medicine to treat stroke. He states that about three in four of critical COVID-19 patients in Intensive Care Units (ICUs) develop clots with their recovery rate critically low. COVID-19 is the respiratory disease caused by the novel coronavirus. He says if the medicine can control these clots, then organ failure and death in many thousands of cases could be avoided. We want COVID-19 patients reaching for the tissue box, not hooked up to ventilators. It could then be a matter of months before doctors around the world can use the novel anti-clotting drug to protect patients with COVID-19, potentially saving thousands of lives, Jackson said. Dr. Jackson said phase-2 trials of the drug, which is administered intravenously, will need to be done overseas because there were not enough severely ill patients on ventilators in Australia.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here